Broilers fed with ButiPEARL™ during the whole production cycle (42 days of age) showed an increased feed conversion ratio and final body weight.
A total of 240 male Ross 308 chicks, at one day old, were divided into 3 experimental groups.
|Treatment Dose||Final Body Weight (g)||Feed Conversion Ratio||Villi Height / Crypt Depth (µm)||ROI|
|Protected Sodium Butyrate 0.1%||2,661||1.60b||5.42a||1.2|
Table 1. Zootechnical performance & intestinal histo-morphological parameters in broiler chickens fed with diets containing different butyrate sources.
Results showed that supplementation with ButiPEARL™ at less than half the dose of the Protected Sodium Butyrate gave better feed conversion ratio (p<0.05), and higher return on investment (ROI*).
*ROI = Net Profit/Treatment Costab means in the same column without a common letter are statistically different
A commercial trial was conducted in Asia using day-old Cobb chicks.
|Treatment Dose||Average Daily Gain (g)||Feed Conversion Ratio||European Broiler Performance Index (EPI)||Intestinal Lesion Score (ILS)||Mortality (%)|
|Difference||+ 0.97||- 0.01
||+ 8.00||- 0.16||- 0.20|
Table 2. Difference in performance and lesion scoring parameters in broiler chickens fed with diets containing either ButiPEARL™ or Avilamycin.
ButiPEARL™ was used to compare against Avilamycin in terms of performance improvement. Overall performance of broilers fed with diets containing
ButiPEARL™ was similar or slightly better than that of broilers fed with diets containing Avilamycin. At the same time, Cobb chicks exhibited a lower intestinal lesion score and a much higher European broiler performance index when fed with diets containing ButiPEARL™.
ButiPEARL™ was able to maintain good animal performance in the absence of Avilamycin, an antibiotic commonly used as growth promoting agent in feed in an unchallenged condition.